The sentinel lymph node biopsy (SLNB) procedure has gained importance now that primary cutaneous melanoma (PCM) patients with a positive sentinel lymph node are considered candidates for adjuvant systemic therapy. However, SLNB is an invasive procedure, and approximately 80% of patients lack nodal metastasis. Many SLNB negative patients are exposed to invasive surgery but enjoy no discernible therapeutic benefit. Therefore, there is a need for a non-invasive test to accurately identify PCM patients who may forgo the SLNB procedure due to low risk of nodal metastasis. Previously, a clinicopathological and gene expression profile model (CP-GEP model) has been developed to identify PCM patients who can safely forgo SLNB. Moreover, a validation of the CP-GEP model in a European cohort has been reported. Here, we describe the validation of the CP-GEP model in a US cohort.
To read this article in full you will need to make a payment
© 2020 European Society for Medical Oncology. Published by Elsevier Inc. All rights reserved.